Regulus Therapeutics
RGLS
#6949
Rank
NZ$0.97 B
Marketcap
NZ$14.12
Share price
0.00%
Change (1 day)
446.62%
Change (1 year)

Revenue for Regulus Therapeutics (RGLS)

Revenue in 2025 (TTM): N/A

In 2024 the company made a revenue of N/A a decrease over the revenue in the year 2023 that were of N/A. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Regulus Therapeutics from 2012 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) N/A
2024 N/A
2023 N/A
2022 N/A
2021 N/A-100%
2020 NZ$13.86 M36.7%
2019 NZ$10.14 M9350.76%
2018 NZ$0.1 M5.88%
2017 NZ$0.1 M-94.12%
2016 NZ$1.72 M-94.32%
2015 NZ$30.33 M209.88%
2014 NZ$9.78 M-58.9%
2013 NZ$23.81 M54.25%
2012 NZ$15.43 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
GlaxoSmithKline
GSK
NZ$73.31 BN/A๐Ÿ‡ฌ๐Ÿ‡ง UK
Sanofi
SNY
NZ$82.26 BN/A๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
NZ$17.42 BN/A๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
NZ$100.61 BN/A๐Ÿ‡ฌ๐Ÿ‡ง UK
Alnylam Pharmaceuticals
ALNY
NZ$5.55 BN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Sangamo Therapeutics
SGMO
NZ$56.9 MN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$83.14 BN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
NZ$0.33 BN/A๐Ÿ‡บ๐Ÿ‡ธ USA